News & Events

Important Information Related to RSV

12/07/2022

Effective November 15, 2022, prior authorization for Syangis is not required.

B – UFC/ACC is pausing prior authorization requirements this season for Synagis® (palivizumab). Effective November 15, 2022, prior authorization for Syangis is not required. This is effective for the remainder of the 2022-23 RSV season.

Quick Links

Crisis Hotlines
Time to Renew
Behavioral Health Services
Benefits & Services
Maternity Care Services
Stay Connected
Frequently Asked Questions